GR3030762T3 - Methods of prolonged suppression of humoral immunity - Google Patents

Methods of prolonged suppression of humoral immunity

Info

Publication number
GR3030762T3
GR3030762T3 GR990401847T GR990401847T GR3030762T3 GR 3030762 T3 GR3030762 T3 GR 3030762T3 GR 990401847 T GR990401847 T GR 990401847T GR 990401847 T GR990401847 T GR 990401847T GR 3030762 T3 GR3030762 T3 GR 3030762T3
Authority
GR
Greece
Prior art keywords
methods
antagonist
humoral immunity
prolonged suppression
suppression
Prior art date
Application number
GR990401847T
Other languages
English (en)
Inventor
Randolph J Noelle
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26813793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3030762(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of GR3030762T3 publication Critical patent/GR3030762T3/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
GR990401847T 1993-09-02 1999-07-14 Methods of prolonged suppression of humoral immunity GR3030762T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11599093A 1993-09-02 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
PCT/US1994/009872 WO1995006480A1 (en) 1993-09-02 1994-09-02 Methods of prolonged suppression of humoral immunity

Publications (1)

Publication Number Publication Date
GR3030762T3 true GR3030762T3 (en) 1999-11-30

Family

ID=26813793

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990401847T GR3030762T3 (en) 1993-09-02 1999-07-14 Methods of prolonged suppression of humoral immunity

Country Status (14)

Country Link
EP (1) EP0742721B1 (el)
JP (1) JP2840131B2 (el)
CN (1) CN1137726C (el)
AT (1) ATE179616T1 (el)
AU (3) AU7643094A (el)
DE (1) DE69418349T2 (el)
DK (1) DK0742721T3 (el)
ES (1) ES2134954T3 (el)
FI (1) FI106927B (el)
GR (1) GR3030762T3 (el)
IL (1) IL110852A (el)
NO (1) NO321037B1 (el)
NZ (1) NZ273208A (el)
WO (1) WO1995006480A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
EP1101495A4 (en) * 1999-06-01 2003-05-07 Eisai Co Ltd PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3308534B2 (ja) * 1991-10-25 2002-07-29 イミュネックス・コーポレーション 新規なサイトカイン
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
CA2089611A1 (en) * 1992-02-17 1993-08-18 Toshiro Yanase Antibacterial porous inorganic capsule and a process for producing the same

Also Published As

Publication number Publication date
FI960979A (fi) 1996-04-30
JP2840131B2 (ja) 1998-12-24
AU7643094A (en) 1995-03-22
ES2134954T3 (es) 1999-10-16
AU1422099A (en) 1999-04-01
DE69418349T2 (de) 1999-09-09
NO960863L (no) 1996-04-30
NZ273208A (en) 2000-12-22
DE69418349D1 (de) 1999-06-10
FI106927B (fi) 2001-05-15
AU2004240180A1 (en) 2005-01-27
WO1995006480A1 (en) 1995-03-09
IL110852A (en) 1999-05-09
CN1137758A (zh) 1996-12-11
EP0742721B1 (en) 1999-05-06
NO960863D0 (no) 1996-03-01
NO321037B1 (no) 2006-03-06
ATE179616T1 (de) 1999-05-15
EP0742721A1 (en) 1996-11-20
JPH09502184A (ja) 1997-03-04
IL110852A0 (en) 1994-11-28
CN1137726C (zh) 2004-02-11
FI960979A0 (fi) 1996-03-01
AU734853B2 (en) 2001-06-21
AU2004240180B2 (en) 2007-08-09
DK0742721T3 (da) 1999-11-01

Similar Documents

Publication Publication Date Title
GR3030762T3 (en) Methods of prolonged suppression of humoral immunity
GR3030568T3 (en) Inducing cytotoxic t lymphocyte responses.
DE122010000016I1 (de) Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
ZA925614B (en) Induction of Cytotixic T-Lymphocyte responses.
NZ510544A (en) Novel adjuvant for subunit or component vaccines
EP0695347A4 (en) METHODS AND SUBSTANCES FOR THE TREATMENT OF INDIVIDUALS INFECTED WITH INTRACELLULAR INFECTIOUS AGENTS
EP0591452A4 (en) Multiple emulsions and methods of preparation
ZA946765B (en) Methods of prolonged suppression of humoral immunity
AU7350798A (en) Corona virus-like particles as tools for vaccination and therapy
ES2012974A6 (es) Mecanismo de articulacion flexible, en particular para unir un pie de microfono a un miembro de base.
DE69837896D1 (de) Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität
DK216789D0 (da) Vandige dispersioner med en synergistisk dispergeringsmiddelkombination samt fremstilling heraf
ZA913071B (en) Treatment
ATA448183A (de) Sitz- und liegemoebel
IT8368342A0 (it) Procedimento e dispositivo per lapreparazione di bevande gassate particolarmente per uso in ambiente domestico
EP0293333A3 (en) A synthetic nonapeptide of use as an adjuvant
ATA401983A (de) Sitz- und liegemoebel
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse
ISHIZAKI Outline of Public Works Research Institute
李兴强 et al. Enhanced expression of Fc receptors after modulation of murine suppressor macrophages by Lipopolysaccharide
SON Use of energy criteria for fracture and fatigue
冯大河 Cloze Test
AU1421492A (en) Ovine adipocyte antigens and their use in the immunological control of fat
GB9124095D0 (en) Improvements in the equipment employed in the combustion of fossil and other fuels